Shilpa Makes Strategic Moves For Growth

Company Acquires FTF Pharma And Auxilla Pharma

 
• By Akriti Seth

Apart from acquiring FTF Pharma and Auxilla, India’s Shilpa Medicare has ramped up its manufacturing to cater to the global market. Having recently launched a new product, the company is feeding its pipeline to ensure that it can keep its growth momentum going.

Growth Strategy on Mechanism of Golden Metallic Gears. Growth Strategy on the Mechanism of Golden Cogwheels with Lens Flare. Growth Strategy - Illustration with Glowing Light Effect.
Shilpa expects growth in the coming quarters • Source: Shutterstock

India’s Shilpa Medicare has announced the acquisition of FTF Pharma and Auxilla Pharmaceuticals and Research in accordance with its aim of diversifying into new therapeutic areas, ramping up its research and development for new products and expanding its portfolio.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Roche Suggests Perjeta Biosimilars May Not Hit Until 2027 ‘Or Later’

 
• By Dean Rudge

Amid several insights into its expectations of biosimilar competition in 2025, Roche has confirmed the total amount it anticipates being shaved from its top line this year.

Hikma Doubles Down On 2025 Guidance Despite Tariff Anxiety And Injectables Competition

 
• By Adam Zamecnik

Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.